

# In silico toxicity evaluation and mode of action prediction based on reference compendia

February 2006 Dr. Hans Gmuender Scientific Consultant


### Toxicogenomics



- + Ideally, safety and efficacy of a new drug is determined simultaneously, enabling qualified decisions for the likelihood of success early in the discovery process
- + Toxicogenomics is the study of how genomes respond to environmental stressors or toxicants
- Toxicogenomics combines classical toxicology and the technologies of -omics and bioinformatics to identify and characterize mechanisms of action of known and suspected toxicants
- + Goals of toxicogenomics:
  - ¬ Prediction of long-term toxicity
  - ¬ Understanding of toxic effects (MOA or MOT)
  - ¬ Identification of cross-species biomarkers
  - ¬ Prediction of MOA of new compounds


### **Research process**





### **Predictive Tox Database**





### Data quality control and data normalization




- + Toxicogenomics is crucially dependent on high quality expression data
- + Data quality control has to ensure:
  - ¬ Data quality assurance over large experimental series
  - ¬ High throughput analysis with standardized data processing
  - ¬ Diagnosis of technically conditioned effects
  - Enabling of consortial work and the submission of toxicogenomics data


### **Refiner Transcriptomics**

- + Detection and correction of defects on microarrays
- + Automated data quality control:
  - Loads uncondensed raw data
  - ¬ Detects and masks defective regions
  - ¬ Detects and corrects gradients and distortions
  - Condenses the data (MAS5, Li-Wong, RMA, GC-RMA)
  - Generates a quality classification for each chip
  - Saves condensed data into database










Classification	Gradi	ent	Severity	Disto	rtion	Severity	Mask	ed Are:	a ( 🛆
	0.00		$\diamond \diamond$	0.02		$\diamond\diamond$	0.08	•	\$
	0.00		$\diamond \diamond$	0.03		$\Leftrightarrow$	0.10	•	\$
	0.00		$\diamond \diamond$	0.03		$\diamond\diamond$	0.11	•	\$
	0.00		$\diamond \diamond$	0.02		$\diamond\diamond$	0.14		\$
	0.00		$\diamond \diamond$	0.02		$\Leftrightarrow$	0.16	\$	\$
	0.00		$\diamond \diamond$	0.02		$\diamond\diamond$	0.17	\$	\$
	0.00		$\diamond \diamond$	0.03		$\diamond\diamond$	0.21	- ¢	\$
	0.01		$\diamond \diamond$	0.02		$\Leftrightarrow$	0.29		\$
	0.00		$\diamond \diamond$	0.02		$\diamond\diamond$	0.30	$\diamond$	\$
	0.00		$\diamond \diamond$	0.01		$\diamond\diamond$	0.55	<ul> <li></li> </ul>	0
	0.00		$\diamond \diamond$	0.01		$\Leftrightarrow$	0.62	\$	۵.

### Workflow for data quality assessment for one-channel data






© 2005 Genedata AG. All rights reserved.


### **Refiner Proteomics**



Compares location of spots over complete gel data set




Automated mismatch detection based on calculation of standardized match scores




### **Refiner Metabolomics**





Baseline subtraction increases the comparability of spectra






### *m/z* alignment prevents false positives in biomarker detection






### **Mapping and normalization**

- + Integration and simultaneous analysis of:
  - ¬ Different Affymetrix chips (e.g. HG-U95 and HG-U133)
  - $\neg$  Chips from different providers (e.g. Affy and Agilent)
  - Chips covering different species (e.g. Mouse and human)
  - Different technologies (transcripts, metabolites, proteins)
- + Normalization:
  - Arithmetic Mean
  - ¬ Logarithmic Mean
  - Median
  - Pointwise Division
  - ¬ LOWESS
  - Half Z-Norm.
  - ¬ Z-Norm.






Mapping of data into a gene symbol space



## **Reference compendium for toxicity prediction**



- + Expression profiles of known, well-described compounds applied under diverse conditions frame a reference compendium
- + The idea of a reference compendium is to predict the 'toxicity' of a new compound (with unknown toxicity) by assigning it to the Tox class of the compounds in the reference compendium with the 'closest' expression profile



Experiments performed with a new compound 3 classified into the 'blue' class 1 classified into the 'red' class

Classified with low affinity into the 'red' class

Reference compendium


### **Detection of significant genes by** unsupervised learning algorithms



+ Unsupervised computational methods can be used to arrange transcripts/proteins/metabolites in groups or clusters based solely on the similarity of their expression

ANOVA

- + Unsupervised learning algorithms
  - ¬ ANOVA (analysis of variance)
  - ¬ N-way ANOVA
  - ¬ Kruskal Wallis ranking test
  - ¬ Principal Components Analysis
  - ¬ Hierarchical clustering
  - ¬ Self-organizing maps
  - K-means clustering




discriminative power as a marker gene

a certain toxic mechanism

### Prediction of toxicity of a new compound using unsupervised learning methods






### **Detection of significant genes by supervised learning algorithms**




- + Supervised learning algorithms predict an output variable (e.g. a toxicity level) from input data (e.g. transcript, protein or metabolite expression)
- + In contrast to unsupervised learning methods a priori knowledge on compounds' 'toxicity' can be taken into account



### **Hypothesis-driven correlation**




+ Identification of relevant associations between sample phenotypes (a priori knowledge) and expression



+ What shall be predicted? Careful selection of hypothesis-driven classifier!




- + Cross validation is a widely used method for estimating the prediction error of a reference compendium
- + The goal of this intrinsic validation is to evaluate whether the reference compendium can be used for predicting the output variable of a compound based on the expression profile





- + Besides the problem of estimating the prediction error, there also exists the issue to identify the set of genes that minimizes the prediction error and are therefore the best 'toxicity' predictors
- + Genes from optimal set of genes are potential biomarkers
- + Supervised learning
  - ¬ Support Vector Machine
  - ¬ Sparse Linear Discriminant Analysis
  - ¬ Fisher Linear Discriminant Analysis
  - K-Nearest Neighbours
- + Gene ranking methods
  - ¬ Sparse Linear Ranking
  - ¬ Supervised Gene Shaving
  - Recursive Feature Elimination
  - ¬ Support Vector Machine
  - ANOVA / Kruskal Wallis




### **Case study**



+	Compounds											
	Clofibrate in 0.9% saline	1	g/kg									
	<ul> <li>DEHP Diethylhexyl phthalate) in distilled water</li> </ul>											
	VPA (Valproic acid) in distilled water	2	g/kg									
+	Single dose (oral administration)											
+	Doses selected to obtain acute hepatotoxicity											
+	Time points: 4h, 24h, 48h, 168h (vehicles: 48h, 168h)											
+	3 - 5 animals / compound and time point											
+	Isolation of total RNA from liver											
+	Hybridization to Affymetrix RG_U34A arrays											
	<ul> <li>Each sample hybridized to a microarray</li> </ul>											
	<ul> <li>Samples from each compound and time point pooled and po hybridized to microarrays</li> </ul>	ol										
+	R. A. Jolly, et al., (2005) <b>Pooling samples within microarray studies: a comparative analysis of rat live</b> <b>transcription response to prototypical toxicants</b> Physiol Genomics, 22, 3, 346-55 GEO Series GSE2303	r										

#### **Principal Components Analysis of all experiments**





- + PCA with 3241 transcripts (detection p-value < 0.04, 50% valid values per group)
- + Clofibrate experiments separated from DEHP and VPA experiments along axis of component 1
- + 24h and 48h experiments separated from vehicle, 4h and 168h experiments along axis of component 2
- + Weak response after 4h
- + Recovery after 168h
- 4h and 168h experiments similar to 48h and 168h vehicle experiments
- + 24h and 48h experiments not clearly separated

### **Clustering of all experiments**



Legend Experiment Groups Clof vehicle, 4h, 168h Clof 24h, 48h DEHP vehicle, 4h, 168h DEHP 24h, 48h VPA vehicle, 4h, 168h VPA 24h, 48h



- + Hierarchical clustering and K-means with 1205 transcripts after ANOVA (p-values < 0.001, fold change ≥ 2, detection p-value < 0.04, 50% valid values per group)
  - + Most up- or down-regulated transcripts after 24h and 48h
  - + Clofibrate experiments separated from DEHP and VPA experiments

#### K-means clustering




## Which data should be selected to build a reference compendium?



- Highly up- or down-regulated transcripts after
   24h and 48h
- Experiment groups 'no or low expression' (4h, 168h, 48h vehicle, 168h vehicle) and 'high expression' (24h, 48h) could be used to build a reference compendium
- + Misclassification rate  $\sim 0\%$


#### **Questions:**

- + Is there enough information in the expression profiles of the 4h and 48h vehicle experiments to use these experiments for a reference compendium?
- + Can these early time points be used to predict outcomes at later time points?



### **Analyses of vehicle and 4h experiments** with transcripts selected from ANOVA






PCA, K-means and hierarchical +clustering with 251 transcripts after ANOVA

(p-values < 0.001, fold change  $\geq$  2, detection p-value < 0.04, 50% valid values per group)


- 4h experiments separated from + vehicle experiments
- Clofibrate experiments separated + from DEHP and VPA experiments

#### K-means clustering



### **Principal Components Analysis of vehicle and 4h experiments**





1084 Items


391 Items

924 Items

### PCA vs. supervised learning




- + PCA is in general not the best method to classify experiment groups as can be seen from the following example
- + The group separation line (decision plane) is in general not parallel to any of the genes or eigen-directions



### **PCA: Classification using PCA**




+ A rotation to the eigenspace therefore does not solve the classification problem



### PCA vs. supervised learning




+ A complete separation of groups is possible by using the coordinate system obtained from the classifier



### **Cross-validation of vehicle and 4h experiments**






© 2005 Genedata AG. All rights reserved.

### Gene ranking to define optimal marker gene set






 + Classifiers: KNN and SLDA all genes (~ 8800) Test Set Fraction: 25 Number of Repeats: 500 Ranking: Sparse Linear Ranking Kernel for SLDA: Linear Distance for KNN: Positive Correlation K: 1

- + Optimal marker gene set consists of ~ 130 genes
- + Prediction error ~ 12 %
- + No significant reduction of prediction error but reduction in number of significant transcripts


<sup>+</sup> Prediction error  $\sim$  15 %

### **Analyses of vehicle and 4h experiments** with optimal marker gene set





30



+ Classifier: K Nearest Neighbours **Distance:** Positive Correlation K: 1

+ No misclassified experiment


 $\bigcirc$ 

 $\mathbf{O}$ 

Pooled vehicle and 4h experiments classified into +compendium consisting of individual vehicle and 4h experiments

**Classification of 'Unknown' compounds** 

Experiment is assigned to the group with highest + affinity








### Pathway characterization and biomarker characterization



- + The reference compendium and the optimal gene set provides the ideal foundation for developing sophisticated MOA models and potential biomarker identification
  - Pathway analysis
  - ¬ Genomic analysis
  - ¬ Promoter analysis
  - ¬ Protein interaction analysis, etc.







## Visualization of hybridization values on individual Affymetrix Chips



+ Visualization of vehicle and 4h experiments hybridization values on probe sets of some transcripts from optimal gene set

 $\Lambda c 2 2 1$ 

D41/3

- + Highly reproducible expression signals
- + Small differences between vehicle and 4h experiments

Comt Cyn(1-2)

			Cyp4azz	ACddI	PUKS	51025830
	Experiment	M93257_s_at	X07259cds_s_at	J02749_at	AF034577_at	rc_AA892522_at
	Clof 48hr Veh1_1		16	16	16	16
Clof 48h	Clof 48hr Veh2_1		16 16	16	16	16
vehicle	Clof 48hr Veh3_1		16	16	16	16
Verneie	Clof 48hr Veh4_1		16	16	16	16
	Clof 48hr Veh5_1		16 16	16	16	16
· · · · ·	Clof 4hr treated1_1		16 16	16	16	16
Clof 4h	Clof 4hr treated2_1		16	16	16	16
	Clof 4hr treated3_1		16	16	16	16
	DEHP 48hr Veh1_1		16 16	16	16	16
DEHP 48h	DEHP 48hr Veh2_1		16 16	16	16	16
	DEHP 48hr Veh3_1		16 16	16	16	16
vehicle	DEHP 48hr Veh4_1		16 16	16	16	16
	DEHP 48hr Veh5_1		16 16	16	16	16
	DEHP 4hr treated1_1		16	16	16	16
DEHP 4h	DEHP 4hr treated2_1		16	16	16	16
	DEHP 4hr treated3_1		16	16	16	16
	VPA 48hr Veh1_1		16	16	16	16
VPA 48h	VPA 48hr Veh2_1		16	16	16	16
	VPA 48hr Veh3_1		16 16	16	16	16
vehicle	VPA 48hr Veh4_1		16	16	16	16
-	VPA 48hr Veh5_1		16 16	16	16	16
	VPA 4hr treated1_1		16	16	16	16
VPA 4h	VPA 4hr treated2_1		16	16	16	16
	VPA 4hr treated3_1		16 16	16	16	16



- + The Fisher's Exact Test is a statistical counting test that assigns statistical significance to statements about the over- or under-representation of properties in a selection group when compared to a so-called universe group.
- + Comparison of optimal gene set from gene ranking against all transcripts

	Suppression				Tr Enhancement						
	- - 10 <sup>-10</sup>	- 10 <sup>-8</sup>	- - 10 <sup>-6</sup>	- 10 <sup>-4</sup>	- 0.01		- 0.01	- 10-4	- 10 <sup>-6</sup>	- 10 <sup>-8</sup>	- 10 <sup>-10</sup>
cellular lipid metabolism											
carboxylic acid metabolism											
fatty acid metabolism											
microbody											
peroxisome											
alkane 1-monooxygenase activity											
lipid biosynthesis											
malate dehydrogenase (decarboxylating) activity											
malate dehydrogenase (oxaloacetate-decarboxylating) (NADP+) activity											
acytransferase activity											
steroid metabolism											
dodecenoyl-CoA delta-isomerase activity											
malic enzyme activity											
sterol metabolism											
C-4 methylsterol oxidase activity											
acyl-[acyl-carrier protein] hydrolase activity											
S-adenosylmethionine-dependent methyltransferase activity											
microtubule organizing center organization and biogenesis											
integral to plasma membrane											
ion transport											

© 2005 Genedata AG. All rights reserved.



### Thank you

Genedata AG Maulbeerstrasse 46 CH-4016 Basel, Switzerland Tel +41 61 697 7651 Fax +41 61 697 7244


www.genedata.com

hans.gmuender@genedata.com

### Consulting study: Prediction of histopathology 'liver necrosis'



- + 52 compounds tested
- + Compounds applied at a low and a high concentration
- + Samples taken after 6h, 24h and 72h
- + Experimental data set included 1597 experiments
- + Histopathological scores assigned to each experiment




+ Prediction error: ~ 10%

### **Consulting study: Prediction of liver toxicity**




- + 33 compounds
- + Compounds applied at a low and a high concentration
- + Samples taken after 6h, 24h and 72h
- + Experimental data set included 958 experiments
- + Toxicity class assigned to each experiment




+ Prediction error: ~ 5%

## Defect detection and masking (perceived as 'spots')






- + Compares the experiments against the corresponding 'reference', identifies systematic deviations as defects and masks them
- + Both dark and bright defects are detected and masked






#### **Signal correction**

- + Divides the reference signal range into stripes
- + In each stripe, determines the median of experiment signals
- + Force this median line to be the diagonal of the new point cloud



© 2005 Genedata AG. All rights reserved.



### **Quality classification and reports**

- + Quality control reports are archived and directly accessible
- + Quality control values are stored in database and accessible for data analysis

Classification	Gradient	Severity	Distortion	Severity	Masked	Area	(△
	0.00	$\diamond \diamond$	0.02	$\diamond\diamond$	0.08 🔳	$\diamond$	$\diamond$
	0.00	$\diamond \diamond$	0.03	$\diamond\diamond$	0.10 🔳	$\diamond$	$\diamond$
	0.00	$\diamond \diamond$	0.03	$\diamond\diamond$	0.11 🔳	$\diamond$	$\diamond$
	0.00	$\diamond \diamond$	0.02	$\diamond\diamond$	0.14 💻	$\diamond$	$\diamond$
	0.00	$\diamond \diamond$	0.02	$\diamond\diamond$	0.16 🗖	$\diamond$	$\diamond$
	0.00	$\diamond \diamond$	0.02	$\Leftrightarrow$	0.17 🗖	$\diamond$	$\diamond$
	0.00	$\diamond \diamond$	0.03	$\diamond\diamond$	0.21 💻	<u>ې</u>	$\diamond$
	0.01	$\diamond \diamond$	0.02	$\Leftrightarrow$	0.29 💻	<b>\</b>	$\diamond$
	0.00	$\diamond \diamond$	0.02	$\Leftrightarrow$	0.30 🗖	<b>\</b>	$\diamond$
	0.00	$\diamond \diamond$	0.01	$\Leftrightarrow$	0.55 💻	٥	٥.
	0.00	$\diamond \diamond$	0.01	$\diamond\diamond$	0.62 💻	۵	۵.


Cartes .	0			51	
	All statistics in the second		And in case of the local division of the loc		
Original	and the second	other address of Address	Contraction of the	Service States	
	Deller an Although			THE REPORT	
	32 . Mil 1993 . S				
	CONDITION CONDITION	101	10 0 m + 10 1	The second second	
	150 A 171 A			A STATE OF	
	and the second second second	ALC: NOT THE OWNER OF	N		
rocessed	ALL DATES CONTRACTOR	and a statement of	And in the second second	COLUMN TWO IS NOT	
In the second	THE APPLY DOT AND	AND A DE AND A DES	A DEAL OF A DEAL OF	TO ALL	
	STREET, STREET, STREET, ST		S 33 30 1. 24	1.12	
	No. 12 Contraction of the	At a weather a state of	the Scientification	and the second second	
	Second Statistics	All Internet and	1 (AN 1975)	and the local division of the	
		THE PLOOP STORE	的 财产 在 计算	CONTRACTOR OF	
110000	金子课的问题的生态呢。		副から見たい時間		
Inelbes	A CONTRACTOR OF A CONTRACTOR OF	1 2	A CONTRACTOR OF A	Concernance and the second	
	The second se		1.50		
	the second s		A second s		
	and the second second	and the second second			
	20				
	Sector States	THE PARTY	1000		
or Ratios		11			
or reation	A REAL PROPERTY.	Contraction of the local division of the loc			
	Processin	a Doculte			
	FIOCESSIN	y Results			
	Set 1 of 3:				
sking	Activity	Result Type	1_blpl_2	2_bipi_2	4_bipi_2
10000500	Load Files	Masked Area (%)	0.10	0.16	0.10
				4-14	
	Chip Statistics	Masked Area (%)	0.10	0.18	0.10
		Outlier Area (%)	0.10	0.16	0.10
		Average Intensity	1878.2	2078.6	1673.9
fects	A Outlier Masking	Masked Area (%)	0.10	0.16	0.10
t Against		Before Correction			
ference		Masked Area (%)	0.10	0.16	0.10
Reservice		After Correction			
				0.30	0.30
	All and the second s	- Discipation data			
	Similarity Analysis	Dissimilarity	0.30	0.30	0.00
	Similarity Analysis	Threshold	0.30	0.50	0.30
	Similarity Analysis	Dissimilarity Threshold Group ID	2	2	2
	/	Threshold Group ID	2	2	2
speriment	Similarity Analysis	Threshold Group ID Within-Group Dis-	0.30 2 0.18		2 0.21
uality	201	Threshold Group ID Within-Group Dis- similarity	2 0.18	2 0.18	2 0.21
nulity	201	Threshold Group ID Within-Group Dis- similarity Within-Group Dis-	2	2	2
radient Sever-	201	Threshold Group ID Within-Group Dis- similarity	2 0.18	2 0.18	2 0.21
uality radient Sever-	200	Threshold Group ID Within-Group Dis- similarity Within-Group Dis- tortion	2 0.18	2 0.18	2 0.21
adity adient Sever- stortion	Reference Experi-	Threshold Group ID Within-Group Dis- similarity Within-Group Dis- tortion	2 0.18	2 0.18	2 0.21
adity adient Sever- stortion averity	2000) 2007 22 Reference Experi- ment	Threshold Group ID Within-Group Dis- similarity Within-Group Dis- tortion	2 0.18 0.24	2 0.18 0.19	2 0.21 0.23
adity adient Sever- stortion averity	20 Reference Experi- ment Defect Masking	Threshold Group ID Within-Group Dis- similarity Within-Group Dis- tortion	2 0.18	2 0.18	2 0.21
uality radient Sever- / istortion eventy	2000) 2007 22 Reference Experi- ment	Threshold Group ID Within-Oroup Dis- similarity Within-Group Dis- tortion Masked Area (%) Before Correction	2 0.18 0.24 0.10	2 0.18 0.19	2 0.21 0.23 0.10
xperiment sealint Sever- y Istortion eventy lasked Area (%)	20 Reference Experi- ment Defect Masking	Threshold Group ID Within-Group Dis- similarity Within-Group Dis- tortion	2 0.18 0.24	2 0.18 0.19	2 0.21 0.23
vality radient Sever- y Istortion eventy	20 Reference Experi- ment Defect Masking	Threshold Group ID Within-Oroup Dis- similarity Within-Group Dis- tortion Masked Area (%) Before Correction	2 0.18 0.24 0.10	2 0.18 0.19	2 0.21 0.23 0.10
vality radient Sever- / istortion eventy	20 20 21 22 23 24 25 26 26 26 27 26 26 27 27 28 27 28 28 29 29 20 20 20 20 20 20 20 20 20 20 20 20 20	Threshold Group ID Within-Group Dis- similarity Within-Group Dis- tortion Masked Area (%) Before Correction Masked Area (%) After Correction	2 0.18 0.24 0.10 0.16	2 0.18 0.19 0.16 0.17	2 0.21 0.23 0.10 0.11
adient Sever-	20 20 22 23 24 25 26 26 27 26 27 27 26 26 27 27 26 26 27 27 27 27 26 26 27 27 27 27 26 26 27 27 26 26 27 26 26 26 26 26 26 26 26 26 26	Threshold Group ID Within-Group Dis- similarity Within-Group Dis- tortion Masked Area (%) Before Correction Masked Area (%) After Correction Gradient Seventty	2 0.18 0.24 0.10	2 0.18 0.19	2 0.21 0.23 0.10
adient Sever-	20 20 21 22 23 24 25 26 26 26 27 26 26 27 27 28 27 28 28 29 29 20 20 20 20 20 20 20 20 20 20 20 20 20	Threshold Group ID Within-Group Dis- similarity Within-Group Dis- tortion Masked Area (%) Before Correction Masked Area (%) After Correction Gradient Severity Before Correction	2 0.18 0.24 0.10 0.18 0.08	2 0.18 0.19 0.16 0.17 0.03	2 0.21 0.23 0.10 0.11 0.04
ality adjent Sever- stortion verity	20 20 22 23 24 25 26 26 27 26 27 27 26 26 27 27 26 26 27 27 27 27 26 26 27 27 27 27 26 26 27 27 26 26 27 26 26 26 26 26 26 26 26 26 26	Threshold Group ID Within-Group Dis- similarity Within-Group Dis- tortion Masked Area (%) Before Correction Masked Area (%) After Correction Gradient Seventty	2 0.18 0.24 0.10 0.16	2 0.18 0.19 0.16 0.17	2 0.21 0.23 0.10 0.11
ality adjent Sever- tortion verity	20 20 22 23 24 25 26 26 27 26 27 27 26 26 27 27 26 26 27 27 27 27 26 26 27 27 27 27 26 26 27 27 26 26 27 26 26 26 26 26 26 26 26 26 26	Threshold Group ID Within-Group Dis- similarity Within-Group Dis- tortion Masked Area (%) Before Correction Masked Area (%) After Correction Gradient Severity Before Correction	2 0.18 0.24 0.10 0.18 0.08	2 0.18 0.19 0.16 0.17 0.03	2 0.21 0.23 0.10 0.11 0.04
adient Sever- stortion verity	20 20 22 23 24 25 26 26 27 26 27 27 26 26 27 27 26 26 27 27 27 27 26 26 27 27 27 27 26 26 27 27 26 26 27 26 26 26 26 26 26 26 26 26 26	Threshold Group ID Within-Group Dis- similarity Within-Group Dis- tortion Masked Area (%) Before Correction Masked Area (%) Mare Correction Gradient Severity Before Correction Gradient Severity After Correction	2 0.18 0.24 0.10 0.10 0.16 0.06 0.00	2 0.18 0.19 0.16 0.17 0.03 0.00	2 0.21 0.23 0.10 0.11 0.04 0.00
adity adient Sever- stortion averity	20 20 22 23 24 25 26 26 27 26 27 27 26 27 27 26 27 27 27 27 27 27 27 27 27 27	Threshold Group ID Within-Occup Dis- similarity Within-Occup Dis- tortion Masked Area (%) Before Correction Gradient Severity After Correction Gradient Severity After Correction Distortion Severity	2 0.18 0.24 0.10 0.18 0.08	2 0.18 0.19 0.16 0.17 0.03	2 0.21 0.23 0.10 0.11 0.04
vality radient Sever- y Istortion eventy	20 20 22 23 24 25 26 26 27 26 27 27 26 27 27 26 27 27 27 27 27 27 27 27 27 27	Threshold Group ID Within-Group Dis- similarity Within-Group Dis- torion Wasked Area (%) Before Correction Gradient Severity After Correction Gradient Severity After Correction Distortion Severity Before Correction	2 0.18 0.24 0.10 0.16 0.06 0.06 0.26	2 0.18 0.19 0.18 0.17 0.03 0.00 0.20	2 0.21 0.23 0.10 0.11 0.04 0.00 0.27
vality radient Sever- y Istortion eventy	20 20 22 23 24 25 26 26 27 26 27 27 26 27 27 26 27 27 27 27 27 27 27 27 27 27	Threshold Group ID Within-Group Dis- similarity Within-Group Dis- tortion Masked Area (%) Before Correction Gradient Severity Before Correction Gradient Severity Before Correction Distortion Severity Distortion Severity Distortion Severity	2 0.18 0.24 0.10 0.10 0.16 0.06 0.00	2 0.18 0.19 0.16 0.17 0.03 0.00	2 0.21 0.23 0.10 0.11 0.04 0.00
vality radient Sever- / istortion eventy	20 20 22 23 24 25 26 26 27 26 27 27 26 27 27 26 27 27 27 27 27 27 27 27 27 27	Threshold Group ID Within-Group Dis- similarity Within-Group Dis- torion Wasked Area (%) Before Correction Gradient Severity After Correction Gradient Severity After Correction Distortion Severity Before Correction	2 0.18 0.24 0.10 0.16 0.06 0.06 0.26	2 0.18 0.19 0.18 0.17 0.03 0.00 0.20	2 0.21 0.23 0.10 0.11 0.04 0.00 0.27
adity adient Sever- stortion averity	20 20 22 23 24 25 26 26 27 26 27 27 26 27 27 26 27 27 27 27 27 27 27 27 27 27	Threshold Group ID Within-Group Dis- similarity Within-Group Dis- tortion Masked Area (%) Before Correction Gradient Severity Before Correction Gradient Severity Before Correction Distortion Severity Distortion Severity Distortion Severity	2 0.18 0.24 0.10 0.16 0.06 0.06 0.26	2 0.18 0.19 0.18 0.17 0.03 0.00 0.20	2 0.21 0.23 0.10 0.11 0.04 0.00 0.27
adient Sever- stortion verity	Reference Experi- ment Defect Masking (Reference) Bignal Correction (Reference)	Threshold Group ID Within-Group Dis- similarity Within-Group Dis- tortion Masked Area (%) Before Correction Masked Area (%) After Correction Gradient Severity After Correction Distortion Severity Before Correction Distortion Severity Distortion Severity After Correction Distortion Severity After Correction Distortion Severity After Correction Distortion Severity After Correction Distortion Severity After Correction	2 0.18 0.24 0.10 0.18 0.06 0.06 0.28 0.02 Qood	2 0.18 0.19 0.18 0.19 0.18 0.17 0.03 0.00 0.20 0.02 Geod	2 0.21 0.23 0.10 0.11 0.04 0.00 0.27 0.03 Good
adient Sever- stortion verity	Reference Experi- ment Defect Masking (Reference) Signal Correction (Reference)	Threshold Group ID Within-Group Dis- similarity Within-Group Dis- torion Masked Area (%) Before Correction Masked Area (%) Before Correction Gradient Severity After Correction Distortion Severity After Correction Mean Expression	2 0.18 0.24 0.10 0.16 0.06 0.06 0.06 0.02	2 2 0.18 0.19 0.19 0.17 0.03 0.03 0.20 0.20 0.20 0.62 Geod 2059.7	2 0.21 0.23 0.10 0.11 0.04 0.00 0.27 0.03
adient Sever- stortion verity	Reference Experi- ment Defect Masking (Reference) Bignal Correction (Reference)	Threshold Group ID Within-Group Dis- similarity Within-Group Dis- tortion Masked Area (%) Before Correction Masked Area (%) After Correction Gradient Severity After Correction Distortion Severity Before Correction Distortion Severity Distortion Severity After Correction Distortion Severity After Correction Distortion Severity After Correction Distortion Severity After Correction Distortion Severity After Correction	2 0.18 0.24 0.10 0.18 0.06 0.06 0.28 0.02 Qood	2 0.18 0.19 0.18 0.19 0.18 0.17 0.03 0.00 0.20 0.02 Geod	2 0.21 0.23 0.10 0.11 0.04 0.00 0.27 0.03 Good
adient Sever-	Reference Experi- ment Defect Masking (Reference) Bignal Correction (Reference)	Threshold Group ID Within-Group Dis- similarity Within-Group Dis- tortion Masked Area (%) Before Correction Gradient Severity Before Correction Gradient Severity Before Correction Gradient Severity After Correction Distortion Severity After Correction Distortion Severity After Correction Classification Mean Expression Gene Outliers (%)	2 0.18 0.24 0.10 0.06 0.06 0.00 0.28 0.02 0.02 0.02 0.02 0.02 0.02	2 0.18 0.19 0.19 0.18 0.17 0.03 0.03 0.00 0.20 0.62 Geod 2069.7 0	2 0.21 0.23 0.10 0.11 0.04 0.00 0.27 0.03 Clood 2111.8 0
ality adjent Sever- stortion verity	Reference Experi- ment Defect Masking (Reference) Bignal Correction (Reference)	Threshold Group ID Within-Group Dis- similarity Within-Group Dis- torion Masked Area (%) Before Correction Masked Area (%) Before Correction Gradient Severity After Correction Distortion Severity After Correction Mean Expression	2 0.18 0.24 0.10 0.18 0.06 0.06 0.28 0.02 Qood	2 2 0.18 0.19 0.19 0.17 0.03 0.03 0.20 0.20 0.20 0.62 Geod 2059.7	2 0.21 0.23 0.10 0.11 0.04 0.00 0.27 0.03 Good 2111.8



### **Tight integration with Affymetrix GCOS**



- + Expressionist offers seamless automated import, pre-processing and analysis of data from GCOS enabling streamlined efficient microarray research
- + Project structure from GCOS is conserved in Expressionist for automated standardized management of huge data sets




 $\odot$  2005 Genedata AG. All rights reserved.

## FASTA information for Affymetrix GeneChips



+ Expressionist provides FASTA information for all Affymetrix GeneChips for in-depth analysis and interpretation of gene expression measurements on the nucleotide level




Tooltip view of probe set GC content view nucleotide sequence

Oligo layer view




#### **Data quality improvement**



#### **Comprehensive mismatch analysis**






### **Signal distribution**




- + Localization of experimental peculiarities:
  - Low match rates due to accumulation of unmatched faint spots in a subset of gels



#### **Baseline adjustment**






© 2005 Genedata AG. All rights reserved.


### m/z alignment







#### **Background correction**





- + Collaborative projects with pharmaceuticals
- + Bioinformatics Partner of several EU funded Tox-related Consortia, including
  - BioCop: New technologies to screen multiple chemical contaminants in foods
  - ¬ NewGeneris: Newborns and genotoxic exposure risks
  - ¬ InnoMed: Predictive toxicology using systems biology approach


# Facilitation of teamwork & project management



+ Share work in progress + Document and report results Abstract No. 68 AN ADDA DREAMING AND EXPRESSION OF HYPOXIA-INDUCIBLE FACTOR-1 AND -2a DURING BOVINE PREIMPLANTATION EMBRYO DEVELOPMENT <u>A. J. Harvey</u>, L. J. Riter and J. G. Thompson Repedictive Medicine Unit, Department of Obstatics and Opsacrings, Universit the of Arbitrary The Oracea Elizabeth Hearing, Wearbrille Read, Wearbrille SA Still + Annotation, publications, wet-lab results The temperal expression of hervine ##" for was determine vs a major role in the regulation of Appart instanting page a maper near in the magnitude or proposition of many different papers including appropriate argums, phones transportent and tracentie growth factors worsonly for the ministenance of homesostatis under specific conditions. Hypotic admittable factor ing (HF-fag at MELI PAS) manuciption factor instantiant in the stoppost proposition experison of these papers 401. HF 221 and concorn a HT Field factor, or modeled of PAS domain Report Collection rotal expression of HIF-Insuggests diff ion was detected in immuture excertes, suggestin Search New Heb hance of HIF-tyneRNA Gene Group: Posttranslational modification, protein turnover, chaperones Gene Gro ved in cultural blue shares 49% homology with the HIF-lagragament Massardy Depart - Depart O Users activates several genes associated with the cospense to (i) (Figure 2). In addition, expression was detected in endotherial and evarian tissue. Gene Group: DNA replication, recombination and repair Gene Group: Cell envelope biogenesis, outer memi Project Broject Group Notes Project B mation has a significant effort on onbeyo in vitro, whereby lower (3-7%) Gene Group: Lipid metabolism Gene Group: Translation, ribosomal structure and biogenes Marne estrations enable greater numbers of embryos is inp to the blastocyst stage. Recently it was shown the Gene Group: Nucleotide transport and metabolism Gene Group: Carbohydrate transport and metaboli perception and the state of the Description Contains iti 🏭 Gene expression e proving of brying HIF-2g in non-culture 0, RAEC (lane 2) and overy (lane 3), and cle-cells (lane-0 and Mastocym (lanes 5 & 6) G Figure 2. Depression of liver dame 13, BAEC da cultured fellicle-cells-three Molecular-marker:pUC19 Gene Group: Energy production and conversion Gene Group: Cell divison and chromosome partitioning 514.15 Contains LunoCastinomas it 🗱 Gene expression expe Start date Defore Gene Description Gene Name E.C. N rish and Methods Discussion We have established, for the first time, that HIF-1g is Gene expression experim Actual and data Equals tine embryos were generated using standard protocols YGR124W asparag Analysis Result Summary ifferentially expressed in bevine embryos, indicating post empaction stages presens a molecular mechanism to 🔁 Oene expression nucleofic 🖬 unded of Projected and date Equals . . . . . YGR138C similarity comparison steps process a solution mechanism to produce approach by Thompson et al. (3) that hyperic instances and the solution of the solution of the boost on early conclusion from comparison is breached for boosts early co-designment. Bit, decrementing that hyperical any be economic during occess gravels and materials. Genedata aw. Teomo YHR208W Project: Lung Oncology @ Nobel Prize Owners Club branche 🗸 Case Sensitive p frozen in aRNA was JL060W similarit n primers. Group 2 Project . Project / 5 apprimers ADDECORD. YKR039W general 12 le stained ord only in that represented HEF-bit scores under a Name Description 2 Groups YLR058C serine to Analysis of farm Pa YLR303W O-acetylk S/G2 Options 4 > = Analysis of: Genes Description and 314 items Valid Values ner Group: 50 Owner Cell No. Creation data 20.108 Available tests: T-Test, Welch, Kolmogorov-Smirnov, Wilcoxof - p53\* Goal - p55-/-N-Fold regulation: None provide demonstration data for classification Group Normalization Settings Status : New project Start date 22-Oct-2002 normal: Globally Normalized Projected and date - p53 \*/\* (2.5 X 10\*) squamous cell lung carcinoma: Globally Normalized Project end information Planned end dat 15-Nev-2002 Actual end date Time (devs) Time (days) Experiment groups **Exported Graphics** 68 experiments of NCI68 set processed by Refin 68 experiments of NCI60 set not processed by Refine unprocessed NCIED data Nucleotide sequence groups А p53+/+ p53-/-С p53+/+ p53-/-D p53-/ There are no nucleolide sequence groups for this project Probe groups HIE-10 > HIE-Iga HIE-1a There are no probe groups for this project 285 • n\$3 -Reports n53@ 185-NCI60 present description 03-Dec-200 supplementary information Actin in pCEP4-HIF-1o: + 02 (%): 20 20 02 (%): 20 1 20 pCMV0: + pCMV-p53: - + B MEF p53+/+ p53-/p53+/+ e537 Page resided: Created by Transit' during section 'Excessiv' on Wed Feb 12 15:50-10 CET 2 [F-1α3 HIE-Ia> p53 > Time (min): 0 20 40 0 20 40 O2 (%): 20 1 20 1

#### Elucidate molecular disease mechanisms -**Cellular regulation**






© 2005 Genedata AG. All rights reserved.

50

#### Elucidate molecular disease mechanisms -Genomic duplications








+ Global view on copy number alterations


Simultaneous Amplicon identification of several experiments



## Gene expression values may depend on selected microarray sequences and on SNPs




- + Match all sequences represented on the microarray onto the genome
- + Investigation of SNPs that may affect the oligonucleotide binding specificity, resulting in reduced hybridization signals






## Potential transcription factor binding sites

- Mapping and alignment onto genome and identification of upstream regions
- + Selection of upstream regions of co-regulated genes for further analysis
- + Identification of motifs for transcription factor binding sites



#### GTTTAA-N (12-15) -GGGTA






# Changes of gene expression of enzymes in metabolic pathways



- + Storing, editing and viewing standard and custom pathway maps, as well as mapping mRNA profiles onto metabolic or regulatory pathways
- + Time series expression profiling






- + A number of genes in rat liver were found to be de-regulated by genotoxic hepatocarcinogens [Ellinger et al. 2004]
- Transcription of a small set of genes behaves similarly (co-expression), suggesting a common molecular mechanism for gene regulation (coregulation)
- + A subset of the co-expressed genes are known p53 targets
- + Are there other transcription factors that might synergize with p53 to coordinate the expression of genes that are induced by genotoxic hepatocarcinogens?
- + To generate new hypotheses different in silico-approaches were used to characterize the promoters of those genes
  - Genome-genome comparisons ("phylogenetic footprinting") a powerful method to deduce regulatory regions in orthologous regions from different species
  - Use of libraries of experimentally derived Transcription Factor Binding Site (TFBS) models for predicting putative TFBSs

#### Comparison of the human and rat BAX gene and identifying conserved upstream regions




 One major application of phylogenetic footprinting is to screen for biologically relevant Transcription Factor Binding Sites (TFBS) based on Position Weight Matrices (PWMs)



#### Identification of human-rodent conserved p53 DNA-binding sites



+ In the BAX promoter region one putative well conserved p53 binding site could be identified upstream of the TSS (site I)




- + Two other p53 binding sites can be identified in less conserved regions.
   One is located further upstream of the TSS (-421 bp; site II), and another in the first intron (+329 bp; site III)
- + Phylogenetic footprinting pinpointed an additional p53 binding site candidate (site III)
- + Future investigation might reveal the functional relevance of this site

## Identification of additional relevant TFBSs




+ The in-silico analysis suggests that besides p53 other mammalian transcription factors that bind in the vicinity of the p53 site might be involved in the regulation of BAX



- + At least 16 TFBS sites could be found in the vicinity of p53 sites that are significantly overrepresented in the regulatory regions of genes shown to be co-expressed under genotoxic stress
- + These factors might cooperate with p53 in the transcriptional activation caused by genotoxic hepatocarcinogens

#### **Predictive Tox Database**





- ...